Drug Trial Radar · NCT06630286
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
609
Actual
Start
Oct 9, 2024
Primary completion
Apr 17, 2026
Study completion Aug 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on B/F/TAF for ≥ 6 months prior to screening. The primary objective is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing B/F/TAF in virologically suppressed PWH at Week 48.
Conditions
- HIV-1-infection
Interventions
ISL/LENDrug
Tablet administered orally
B/F/TAFDrug
Tablet administered orally
PTM B/F/TAFDrug
Tablet administered orally
PTM ISL/LENDrug
Tablet administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants with HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-Defined Snapshot AlgorithmTime frame: Week 48
Locations
106 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Pueblo Family Physicians
Phoenix, Arizona
Kaiser Permanente Southern California
Los Angeles, California
Ruane Clinical Research Group, Inc
Los Angeles, California
Mills Clinical Research
Los Angeles, California
BIOS Clinical Research
Palm Springs, California
Optimus Medical Group
San Francisco, California
Vivent Health
Denver, Colorado
University of Colorado- Anschutz Medical Campus - PPDS
Denver, Colorado
Yale University
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Whitman-Walker Health
Washington D.C., District of Columbia
CAN Community Health
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
CAN Community Health
Miami Gardens, Florida
Midland Research Group, Inc.
Oakland Park, Florida
Orlando Immunology Center
Orlando, Florida
AHF (AIDS Healthcare Foundation) - Pensacola Research
Pensacola, Florida
CAN Community Health
Sarasota, Florida
St. Josephs Comprehensive Research Institute
Tampa, Florida
Emory University
Atlanta, Georgia
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Mercer University
Macon, Georgia
Chatham CARE Center
Savannah, Georgia
Howard Brown Health
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
The Brigham and Women's Hospital, Inc.
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
Community Research Initiative
Boston, Massachusetts
Be Well Medical Center
Berkley, Michigan
Trinity Health
Grand Rapids, Michigan
KC CARE Health Center
Kansas City, Missouri
ID CARE
Hillsborough, New Jersey
Saint Michael's Medical Center
Newark, New Jersey
South Jersey Infectious Disease
Somers Point, New Jersey
AXCES Research Group - Albuquerque
Santa Fe, New Mexico
Brooklyn Clinical Research Center
Brooklyn, New York
New York Presbyterian Hospital
Flushing, New York
Jacobi Medical Center
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.